
Global R&D Pipeline
My Favorite
Hot Targets:
ITGA2&ITGB1
Back
Total number of drugs
5
Phase II and later clinical stages
0%
Involving companies
4
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PA-0661 | PA-0661 | Monoclonal antibody | Neoplasms Skin and Musculoskeletal Diseases | Cadherin 5 inhibitors Integrin alpha2/beta1 agonists | Protein Alternatives SL | Protein Alternatives SL | Preclinical | PA-0661 | detail > | ||||||||||||
| BTT-3033 | BTT-3033 | Small molecule drug | Integrin alpha2/beta1 antagonists | Biotie Therapies Oy | Discontinued | BTT-3033 | detail > | ||||||||||||||
| BTT-3034 | BTT-3034 | Small molecule drug | Integrin alpha2/beta1 antagonists | Biotie Therapies Oy | Discontinued | BTT-3034 | detail > | ||||||||||||||
| EMS-16 | EMS-16 | Small molecule drug | Neoplasms | Integrin alpha2/beta1 antagonists | Biogen, Inc. | Discontinued | EMS-16 | detail > | |||||||||||||
| Integrin α2β1 regulates(University of California San Francisco) | Integrin α2β1 regulates(University of California San Francisco) | Small molecule drug | Immune System Diseases Respiratory Diseases | Integrin alpha2/beta1 antagonists | The University of California, San Francisco | Preclinical | Integrin α2β1 regulates(University of California San Francisco) | detail > |
Total 5 data
1


